Tumefactive demyelination and a malignant course in an MS patient during and following fingolimod therapy

@article{Hellmann2014TumefactiveDA,
  title={Tumefactive demyelination and a malignant course in an MS patient during and following fingolimod therapy},
  author={M. Hellmann and N. Lev and I. Lotan and R. Mosberg-Galili and E. Inbar and J. Luckman and S. Fichman-Horn and M. Yakimov and I. Steiner},
  journal={Journal of the Neurological Sciences},
  year={2014},
  volume={344},
  pages={193-197}
}
Finglimod, a sphingosine 1-phosphate receptor modulator, is the first orally administered therapy approved for prophylaxis in multiple sclerosis (MS). Several reports in the last two years suggested that it might be associated with severe augmentation of disease activity upon initiation or discontinuation of therapy. We present an MS patient who developed a giant cavitating brain lesion under fingolimod and in whom cessation of therapy was associated with a very active course. Brain biopsy… Expand
Early relapse with tumefactive MS lesion upon initiation of fingolimod therapy
TLDR
The case of a 47-year-old male MS patient with a severe relapse related to a tumefactive brain lesion, occurring 10 days after initiation of fingolimod therapy, and development of a TDL, which might indicate a shift in the immune response triggered by the fingolIMod-induced cellular redistribution in susceptible individuals is presented. Expand
Tumefactive multiple sclerosis lesions associated with fingolimod treatment: Report of 5 cases.
TLDR
The etiopathogenic association between fingolimod and TDLs is not clear, but given the increasing reports of cases it should be taken into account for treatment selection in patients with this type of lesions. Expand
Systemic Lupus Erythematous Emergence in a Multiple Sclerosis Patient Treated with Fingolimod
TLDR
A case of a female patient with MS who experienced arthritis and SLE presentation after FIN treatment, the first oral drug approved to treat relapsing forms of MS is discussed. Expand
Multiple sclerosis treatment with fingolimod: profile of non-cardiologic adverse events
TLDR
The present review lists the non-cardiologic adverse events that all neurologists prescribing fingolimod should be aware of, and its first hours of use are associated with related to S1P receptors in the heart. Expand
Rebound Syndrome in Patients With Multiple Sclerosis After Cessation of Fingolimod Treatment.
TLDR
These cases provide evidence for a fingolimod rebound syndrome at a clinically relevant frequency, highlighting the need to determine the best methods for sequencing or discontinuing MS therapies. Expand
Patient experience and practice trends in multiple sclerosis – clinical utility of fingolimod
TLDR
Although multiple benefits in treatment of multiple sclerosis including high efficacy and ease of administration, potential untoward effects such as cardiotoxicity, risk of infection, and cancer exist, thus mandating careful screening and frequent monitoring of patients undergoing treatment with fingolimod. Expand
Tumefactive multiple sclerosis in association with fingolimod initiation and discontinuation
TLDR
TMS should be considered when a severe or atypical MS relapse occurs shortly after fingolimod initiation or discontinuation, and should prompt imaging evaluation and appropriate treatment initiation. Expand
[A case of multiple sclerosis who relapsed early after fingolimod therapy introduced].
TLDR
Careful determination and observation are required upon the FTY administration into the MS with high frequency of relapse, as brain MRI showed more than 20 several millimeter Gd enhanced lesions in periventricular white matter, juxta-cortical white matter and cerebellum. Expand
Clinical efficacy, safety, and tolerability of fingolimod for the treatment of relapsing-remitting multiple sclerosis
TLDR
The aim of this review is to describe and discuss the characteristics of fingolimod concerning its efficacy, safety, and tolerability in the clinical context of multiple sclerosis management. Expand
Catastrophic Magnetic Resonance Images in the Central Nervous System of Patients Undergoing Treatment with Fingolimod
TLDR
Two new cases of very extensive lesions on MRI in brain and spinal cord associated with use of fingolimod are presented and patients’ disabilities are described in terms of their EDSS (Expanded Disability Scale Score). Expand
...
1
2
3
...

References

SHOWING 1-10 OF 24 REFERENCES
Tumefactive multiple sclerosis lesions under fingolimod treatment
Fingolimod is an oral sphingosine 1-phosphate receptor modulator that prevents recirculation of lymphocyte subsets from lymph nodes. It decreases the number of relapses, slows the progression ofExpand
Emerging tumefactive multiple sclerosis after switching therapy from natalizumab to fingolimod
TLDR
A multiple sclerosis patient who developed a relapse with magnetic resonance imaging (MRI) features of tumefactive demyelination after switching therapy from natalizumab to fingolimod may have been caused by the change in immunotherapy. Expand
HEMORRHAGING FOCAL ENCEPHALITIS UNDER FINGOLIMOD (FTY720) TREATMENT: A CASE REPORT
TLDR
A case of severe hemorrhagic focal encephalitis is presented in a 28-year-old woman with mild RRMS during treatment with fingolimod in the FREEDOMS II trial, which would be a milestone in MS treatment. Expand
Tumefactive MS lesions under fingolimod
TLDR
The authors' observations add further evidence for the development of atypical demyelinating lesions in some patients receiving fingolimod, which might be related to a treatment-associated shift in the immunopathology of specifically susceptible individuals. Expand
Rebound after Fingolimod suspension in a pediatric-onset multiple sclerosis patient
TLDR
In the POMS patient, Fingolimod was not effective to contain the inflammatory process and the drug discontinuation resulted in a rebound phenomenon, although this was observed during a phase of continuing disease activity rather than in the context of quiescent disease. Expand
Severe multiple sclerosis relapse under fingolimod therapy: Incident or coincidence?
TLDR
Fingolimod is the first orally administered disease-modifying drug that has been approved for treatment of relapsing-remitting multiple sclerosis and acts as a nonselective functional antagonist of the sphingosine-1-phosphate receptor family, trapping B and T lymphocytes in secondary lymphoid tissues. Expand
Disease reactivation after fingolimod discontinuation in two multiple sclerosis patients
TLDR
Fingolimod (FTY) is the first oral drug approved for relapsing-remitting (RR) multiple sclerosis (MS) and two MS patients with massive disease reactivation after FTY discontinuation are described. Expand
Rebound of disease activity after withdrawal of fingolimod (FTY720) treatment.
TLDR
Two aspects relevant to any newly approved multiple sclerosis treatment with immunomodulatory properties are highlighted with this case: possible rebound of disease activity after discontinuation; second, the occurrence of a tumor as a possible treatment-related complication. Expand
Severe multiple sclerosis reactivation under fingolimod 3 months after natalizumab withdrawal
TLDR
The case of a woman with multiple sclerosis who developed a severe neurological condition following natalizumab (NZB) withdrawal and soon after fingolimod (FTY) initiation suggests that FTY introduction may occur less than three months after NZB withdrawal. Expand
Frequent early multiple sclerosis relapses during treatment with fingolimod: a paradoxical effect?
TLDR
Observations on frequent early relapses in patients commencing FTY at the Center for Demyelinating Diseases of Modena, Italy are shared, suggesting that early relapse during FTY treatment could be explained by a transient reduction of T regulatory cells (Treg), or of their immunosuppressive activity, although data is contradictory. Expand
...
1
2
3
...